KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Equity Income: 2009-2012

Historic Equity Income for Alnylam Pharmaceuticals (ALNY) over the last 4 years, with Dec 2012 value amounting to -$4.5 million.

  • Alnylam Pharmaceuticals' Equity Income rose 7.65% to -$881,000 in Q4 2012 from the same period last year, while for Dec 2012 it was -$4.5 million, marking a year-over-year decrease of 29.02%. This contributed to the annual value of -$4.5 million for FY2012, which is 29.02% down from last year.
  • Latest data reveals that Alnylam Pharmaceuticals reported Equity Income of -$4.5 million as of FY2012, which was down 29.02% from -$3.5 million recorded in FY2011.
  • In the past 5 years, Alnylam Pharmaceuticals' Equity Income ranged from a high of -$3.5 million in FY2011 and a low of -$7.6 million during FY2010.
  • Its 3-year average for Equity Income is -$5.2 million, with a median of -$4.5 million in 2012.
  • In the last 5 years, Alnylam Pharmaceuticals' Equity Income tumbled by 55.58% in 2010 and then skyrocketed by 54.12% in 2011.
  • Alnylam Pharmaceuticals' Equity Income (Yearly) stood at -$4.9 million in 2009, then crashed by 55.58% to -$7.6 million in 2010, then skyrocketed by 54.12% to -$3.5 million in 2011, then dropped by 29.02% to -$4.5 million in 2012.